Saturday, Takeda And Pfizer Announced Presentation Of Phase 3 HD21 Trial Results Evaluating Adcetris (Brentuximab Vedotin) In Combination With Chemotherapy At The American Society Of Clinical Oncology And European Hematology Association Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Takeda and Pfizer announced positive Phase 3 HD21 trial results for Adcetris (Brentuximab Vedotin) in combination with chemotherapy, showing superior progression-free survival and improved tolerability compared to the current standard of care in Europe.
June 03, 2024 | 9:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's collaboration with Takeda on the Phase 3 HD21 trial for Adcetris shows promising results, which could positively impact Pfizer's stock price.
The successful trial results could enhance Pfizer's oncology portfolio and lead to increased revenue, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Takeda's Phase 3 HD21 trial results for Adcetris show superior progression-free survival and improved tolerability, which could boost the company's stock price.
The positive trial results for Adcetris could lead to increased adoption and sales, positively impacting Takeda's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100